ApoPharma
Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
Conditions: Iron Overload
Patients who have iron overload due to chronic blood transfusions and have developedheart failure or who are at high risk of heart failure because of the high levels of ironin their hearts, will be treated with deferiprone, an investigational drug, incombination with deferoxamine (Desferal). Some studies suggest that deferiprone may bebetter than deferoxamine in removing iron from the heart and improving heart function,and that using both drugs together may remove more iron. Participants would make a clinicvisit for lab studies each week, and would continue to take deferiprone for as long astheir physician feels it is useful in their care.
Tibotec Pharmaceuticals, Ireland
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
Conditions: HIV Infections
The purpose of this study is to provide early access to TMC114 (a protease inhibitor) forHIV-1 infected patients with limited or no treatment options, who have failed multipleantiretroviral (ARV) regimens, and to evaluate the longer-term safety and tolerability ofTMC114/r in combination with other antiretrovirals
AIM ImmunoTech Inc.
Ampligen in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome
This is an open label study of Ampligen in patients with chronic fatigue syndrome.
Pfizer
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell
The primary objective of this protocol is to provide access to SU011248 treatment forpatients with metastatic RCC who are ineligible for participation in ongoing SU011248clinical studies and have the potential to derive clinical benefit from treatment withSU011248 based on the judgment of the investigator.
Boehringer Ingelheim
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
Conditions: HIV Infections
This study was designed to provide early access to and evaluate the safety of TPV/r inPI-experienced patients with HIV-1 infection.
Pfizer
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Conditions: Gastrointestinal Neoplasm
The purpose of this study is to permit access to SU011248 for treatment use by patientswith GIST given the following conditions: a) patients undergo screening, but are noteligible for participation in ongoing clinical studies such as A6181004; AND b) patientshave GIST which standard treatments have not been able to control with acceptabletoxicity AND c) patients have the potential to derive clinical benefit from treatmentwith SU011248.
Boehringer Ingelheim
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
Conditions: HIV Infections
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavircombined with low dose of ritonavir in patients with progressive, HIV-1 disease who havefailed or are intolerant to currently approved treatments for HIV infection, who areunable to participate in another tipranavir controlled clinical trial and have an urgentneed for anti-HIV treatment.
Eli Lilly and Company
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Conditions: Mesothelioma
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTAalone on you and your malignant pleural mesothelioma as well as make ALIMTA available topatients who qualify for treatment.
Cancer Commons
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Conditions: Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, HepatoCellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
The objective of this expanded access program is to provide ulixertinib (BVD-523) forcompassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s),including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who haveincomplete response to or have exhausted available therapies.Ulixertinib is available for treatment as monotherapy or in combination with otherclinically tolerable agent(s), conditionally approved by the drug manufacturer.
Chiesi USA, Inc.
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
Conditions: Fabry Disease
The objective of this treatment protocol is to provide guidance to Treating Physicianswho seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, inthe opinion of the Treating Physician, requires treatment with enzyme replacement therapy(ERT) with pegunigalsidase alfa and a) cannot be adequately treated with currentlyapproved FDA products and/or b) are not able or willing to participate in any of theon-going clinical trials in the United States.